Viatris Agrees to Buy Pacira for $36.50 a Share in Cash, $1.65B Deal

Viatris Inc. agreed on 8 October 2026 to acquire Pacira BioSciences, Inc. for $36.50 per share in cash, an aggregate equity value of about $1.65 billion. The two companies announced the definitive agreement in a joint press release. Both boards have approved the deal, and the companies expect it to close by the end of 2026.

How much is Viatris paying for Pacira, and when was the deal agreed?

Viatris will pay $36.50 per share in cash for Pacira's outstanding common shares, Indian Pharma Post reported. The aggregate equity value is approximately $1.65 billion, and the deal is all cash. The agreement is dated 8 October 2026, according to the joint press release.

How is the deal structured?

The deal uses two steps, and both are priced at the same figure. In step one, Viatris launches a tender offer for Pacira's outstanding common shares at $36.50 in cash. Shareholders who tender their shares in that offer are paid through it.

In step two, any shares that are not tendered are acquired in a second-step merger on the same terms. The first step is the main purchase, and the second step covers whatever shares remain. Neither step changes the price, so the structure does not offer one holder a better figure than another.

Because the merger uses the same price, a shareholder who does not tender still receives $36.50 per share. Indian Pharma Post does not say whether a shareholder vote is needed for the second step.

What has to happen before the deal closes?

Completion depends on two conditions. A majority of Pacira's outstanding shares must be tendered, and the applicable regulatory waiting period must expire. Indian Pharma Post describes both as customary closing conditions.

The sources do not name the regulator or give a date for the end of the waiting period.

How will Viatris pay for the acquisition?

Viatris plans to fund the acquisition primarily from excess cash, with the remainder covered by short-term borrowings. Indian Pharma Post and the joint press release report the same plan. None of the three sources gives the size of the borrowing or the share of cash.

Have both boards approved the deal?

Yes. The boards of Viatris and Pacira both unanimously approved the transaction, and Pacira's board unanimously recommended that shareholders tender their shares, Indian Pharma Post reports. The joint press release confirms that Viatris and Pacira entered into a definitive agreement.

When is the deal expected to close?

The companies expect the acquisition to close by the end of 2026, subject to customary closing conditions and regulatory requirements. That is an expectation, not a fixed date. The closing depends on the tender result and the regulatory waiting period, and neither has a date in the sources used here.

What is the timeline so far?

The dates in the sources run in a clear order. Each date below is when that source was published, not when the deal was agreed. The agreement date is 8 October 2026, the date the sources give for the definitive agreement. Viatris and Pacira announced the definitive agreement on 8 October 2026, according to the joint press release distributed through PR Newswire. Indian Pharma Post published its report on 11 October 2026, and it describes the deal as Viatris agreeing to acquire Pacira BioSciences for $1.65 billion. A third report, from BHC Media and dated 20 October 2026, gives the same 8 October date for the definitive agreement. The companies expect the deal to close by the end of 2026. Between the agreement and that expected close, the two events the sources name are the tender of a majority of Pacira's shares and the expiration of the regulatory waiting period.

Which sources say what?

Three sources cover the deal, and they describe the same terms. Only the PR Newswire release comes from the companies themselves. Indian Pharma Post is a news write-up that reports the terms after the announcement. BHC Media, which published on 20 October 2026, reports the 8 October agreement date and the plan to fund the deal primarily from excess cash, with the remainder from short-term borrowings.

Indian Pharma Post is the source for the $36.50 cash price, the $1.65 billion aggregate equity value, the tender offer and second-step merger, the closing conditions, the expected closing by the end of 2026, and the funding plan. The joint press release is the source for the 8 October agreement date. Where a figure in this post needs a citation, the link points to the source that reports it.

What's still unclear?

• One company source. The joint press release is the only company-issued source. Indian Pharma Post reports the same terms after the announcement, so it is not independent confirmation of them.
• The regulatory timeline is undated. The sources name a waiting period but not the regulator or its length, so the end-of-2026 target has no stated milestone.
• The second-step mechanics are thin. The sources do not explain how the merger is approved or how dissenting shareholders are treated.
• The funding split is not quantified. "Primarily from excess cash" and "the remainder from short-term borrowings" give no amounts.